Offsets deal reached to fund US FDA, NIH 'Cures' bill
This article was originally published in SRA
Republican and Democratic leaders of the US House energy and commerce committee late on 20 May said they had reached a deal on how they will pay for the expected $13bn costs of implementing the provisions in the proposed 21st Century Cures Act (HR 6). The bill is aimed at overhauling the US biomedical enterprise, and is intended to speed up the discovery, development and approval processes for therapies, devices and diagnostics1.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.